Clinical trials: Liver Graft Dysfunction
End Stage Liver Disease
Study of Peripheral Tissue Oxygenation in End-stage Liver Disease Patients During Liver Transplantation
End - stage liver disease can cause many problems to the patients including fatigue, weakness,jaundice, confusion, abdominal pain and distension. Another important problem is the cardiovascular system (heart and blood vessels).
- Trial name
- NCT01794637
- Where
- Canada
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatitis C
Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)
The overall aim of this study is to evaluate the prevalence of cognitive impairments and brain anomalies in Chronic Hepatitis C infected individuals and to investigate likely changes in cognition and brain structure and function…
- Trial name
- CICHepC (NCT02745132)
- Testing
- Neuropsychological evaluation and Brain MRI
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Liver Dysfunction
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
INTERLIVER is a prospective observational study of the relationship of the molecular phenotype of 300 liver transplant biopsies to the histologic phenotype and the clinical features and outcomes.
- Trial name
- INTERLIVER (NCT03193151)
- Testing
- liver biopsy
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 300 people
- Sponsor
- University of Alberta
Liver Transplant, Liver Steatosis
Controlled Attenuation Parameter (CAP) in Liver Allografts
The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze…
- Conditions
- Liver Transplant, Liver Steatosis, Liver Disease, Primary Non-function
- Trial name
- NCT02798861
- Testing
- Fibroscan 402/530
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Andres Duarte-Rojo
Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease
Positive Association of US-FLI With the Severity of CAD
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography
- Trial name
- NCT06541132
- Testing
- Observational study without human intervention
- Where
- China
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Postoperative Cognitive Complications, Delirium
Prospective Observational Multimodal Neuromonitoring During High-Risk Adult Surgery
This is a prospective observational cohort study of adult patients undergoing high-risk surgery at UT Southwestern Medical Center.
- Conditions
- Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries
- Trial name
- NCT07577726
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Diseases, Intra-Abdominal Hypertension
Organ Dysfunction Associated With Intra Abdominal Pressures in Liver Transplantation
Patients with end stage liver disease have varying degrees of intra-abdominal hypertension (IAH) due to the presence of ascites. The perioperative events may either relieve or aggravate the intra-abdominal pressures.
- Conditions
- Liver Diseases, Intra-Abdominal Hypertension, Cirrhosis, Liver, Organ Dysfunction Syndrome
- Trial name
- OIL (NCT04463745)
- Where
- India
- Volunteers
- 25 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Liver Transplant; Complications
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation
the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft…
- Trial name
- NCT05031026
- Testing
- Dexmedetomidine, Normal Saline
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Organ Donation, Liver Transplantation
EPI-STORM: Cytokine Storm in Organ Donors
Kidney and liver transplantation are the treatment of choice and are often the last therapeutic option offered to patients with chronic renal and liver failure.
- Conditions
- Organ Donation, Liver Transplantation, Kidney Transplantation, Graft Dysfunction
- Trial name
- EPI-STORM (NCT03786991)
- Testing
- No intervention
- Where
- 4 sites in Canada
- Volunteers
- 105 people
- Sponsor
- Université de Sherbrooke
Liver Transplantation, Acute Kidney Injury
Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver…
- Trial name
- HALT (NCT06535945)
- Testing
- Albumin administration
- Where
- 8 sites in France
- Volunteers
- 400 people
- Sponsor
- Rennes University Hospital
Early Allograft Dysfunction, Ischemic Reperfusion Injury
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
The purpose of this study is to determine whether the Tacrolimus added to histidine-tryptophan-ketoglutarate (HTK) solution given through intraportal and intraarterial infusion during back-table procedure is capable of reducing…
- Conditions
- Early Allograft Dysfunction, Ischemic Reperfusion Injury, Liver Transplantation, Hyperfibrinolysis
- Trial name
- PATAC (NCT01887171)
- Testing
- Tacrolimus
- Where
- Belarus
- Volunteers
- 86 people
- Sponsor
- Republican Scientific and Practical Center for Organ and Tissue Transplantation
Sexual Dysfunction in Patients With Cirrhosis Awaiting Liver Transplantation
Sexual Dysfunction in Cirrhosis
The prevalence of erectile dysfunction (ED) is about 10% in the general population, but increases with age, ranging from 9.1% in men 40-49 years to 55% in men >70.
- Trial name
- SEDYC (NCT05428267)
- Testing
- questionnaire, blood collection
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Transplant; Complications
Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant
In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury.
- Trial name
- NCT04324255
- Testing
- LT
- Where
- South Korea
- Volunteers
- 1,199 people
- Sponsor
- Asan Medical Center